Concomitantly to the everolimus DFCI study, the COG ADVL1114 phase I study (NCT01403415) explored the safety and preliminary activity of the mTOR inhibitor temsirolimus (three weekly doses) in combination with an intensive reinduction chemotherapy (UK ALLR3) for 2nd or greater relapse of pediatric ALL. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.